Table 5. Change in blood vessel and muscle inflammation factors for 12 weeks training in each supplement group.
| Variable | Group | Training period (week) | p | η2 | ||||
|---|---|---|---|---|---|---|---|---|
| 0 | 4 | 8 | 12 | |||||
| CRP (mg/dl) |
Pla | 0.03 ± 0.03 |
0.05 ± 0.06 |
0.11 ± 0.11 |
0.05 ± 0.02 |
Ex Suppl Ex x Suppl |
0.066 0.924 0.044† |
0.150 0.001 0.170 |
| Pro | 0.07 ± 0.10 |
0.06 ± 0.08 |
0.06 ± 0.06 |
0.05 ± 0.03 |
||||
| CK (U/l) |
Pla | 176.6 ± 124.8 |
127.3 ± 50.4 |
166.4 ± 33.9 |
223.1 ± 58.4 |
Ex Suppl Ex x Suppl |
0.024† 0.485 0.534 |
0.208 0.031 0.038 |
| Pro | 165.1 ± 65.4 |
172.4 ± 60.4 |
194.8 ± 60.4 |
228.7 ± 108.2 |
||||
| LDH (U/l) |
Pla | 318.0 ± 30.9 |
307.5 ± 34.6 |
354.9 ± 37.3 |
346.6 ± 41.3 |
Ex Suppl Ex x Suppl |
0.000††† 0.370 0.634 |
0.467 0.051 0.029 |
| Pro | 296.7 ± 32.6 |
297.4 ± 40.2 |
333.2 ± 37.0 |
341.7 ± 56.2 |
||||
Note. Data are means ± S.D. Pla: placebo group, Pro: protein supplement group, Ex: exercise, Suppl: supplement, CRP: C-reactive protein, CK: creatine kinase, LDH: lactate dehydrogenase
†Significant interaction or main effect, p <0.05.
†††Significant interaction or main effect, p <0.001.